Performance evaluation of phage-displayed synthetic human single-domain antibody libraries: A retrospective analysis

J Immunol Methods. 2018 May:456:81-86. doi: 10.1016/j.jim.2018.02.009. Epub 2018 Feb 17.

Abstract

Fully human synthetic single-domain antibodies (sdAbs) are desirable therapeutic molecules but their development is a considerable challenge. Here, using a retrospective analysis of in-house historical data, we examined the parameters that impact the outcome of screening phage-displayed synthetic human sdAb libraries to discover antigen-specific binders. We found no evidence for a differential effect of domain type (VH or VL), library randomization strategy, incorporation of a stabilizing disulfide linkage or sdAb display format (monovalent vs. multivalent) on the probability of obtaining any antigen-binding human sdAbs, instead finding that the success of library screens was primarily related to properties of target antigens, especially molecular mass. The solubility and binding affinity of sdAbs isolated from successful screens depended both on properties of the sdAb libraries (primarily domain type) and the target antigens. Taking attrition of sdAbs with major manufacturability concerns (aggregation; low expression) and sdAbs that do not recognize native cell-surface antigens as independent probabilities, we calculate the overall likelihood of obtaining ≥1 antigen-binding human sdAb from a single library-target screen as ~24%. Successful library-target screens should be expected to yield ~1.3 human sdAbs on average, each with average binding affinity of ~2 μM.

Keywords: Human V(H)/V(L); Phage display; Single-domain antibody; Synthetic antibody.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antigen-Antibody Reactions
  • Antigens / genetics
  • Antigens / immunology*
  • Humans
  • Peptide Library*
  • Retrospective Studies
  • Single-Domain Antibodies / genetics
  • Single-Domain Antibodies / immunology*
  • Solubility

Substances

  • Antigens
  • Peptide Library
  • Single-Domain Antibodies